Mr. Clement Forget reports

CLEMEX DISCLOSES FIRST QUARTER RESULTS OF 2015 INFORMS ITS SHAREHOLDERS OF A NOTICE RECEIVED WITH REGARDS TO BY-LAW NO. 4

Clemex Technologies Inc. has released its financial results for the first quarter of fiscal year 2015 ending July 31, 2014. Sales reached $1,568,039, compared with $1,042,744 for the same period last year. The increase in sales combined with a higher gross margin of 52.5 per cent for this first quarter allows the corporation to end the quarter with a net loss of $34,915 ($34,165 attributable to Clemex), compared with a net loss of $267,375 ($256,567 attributable to Clemex) posted last year.

During this third quarter, the corporation made several sales to major clients in the manufacturing sector in North America, such as Carestream, Minn.; Sensata Technologies, Mass.; Evraz Rocky, Colo.; and Gerdau, Ariz. As for sales abroad, sales were made in India to Goodrich Aerospace and to Syngene International. In Canada, the corporation made a few important sales, one of which was to SGS Canada, Ont., and some microscopes were sold to the education sector in the province of Quebec.

                       FINANCIAL HIGHLIGHTS
                  
                                          Q1 2015           Q1 2014

Sales                                   1,568,039         1,042,744
Gross margin                              823,340           520,095
Gross margin %                               52.5%             50.1%
Total operating expenses                  797,393           809,493
Income taxes                               29,500             2,350
Net result                                (34,915)         (267,375)
Net result attributable to
Clemex Technologies                       (34,165)         (256,567)     
Global result per share                         
(basic and diluted)                        (0.001)           (0.008) 

Clement Forget, president and chief executive officer of Clemex Technologies, declared: "We are quite pleased with our sales in this quarter. While [the first quarter] is traditionally the slowest in sales activity of all four quarters for the company, and despite a slight drop in sales in Canada, North America sales rose by more than 80 per cent this year, reaching $1,220,619 while they were $668,948 for the same quarter last year. We sincerely hope that this long-waited regain in manufacturing activity in the [United States] is here to stay, and that the sector continues to grow since sales in all other countries outside North America remained nearly stable at $347,420, compared to $373,796 for this first quarter.

"With regard to the undergoing project of development of our hematology instruments," Mr. Forget continued, "this project continues to be demanding in terms of resources, as the team is finalizing the [International Organization for Standardization] accreditations and validation procedures prior to our submission to Health Canada. The company is following its business and marketing plan set forward for the business development in the biomedical field, which includes commercial work. For that purpose and for the third consecutive year, the company participated again this summer in two major trade shows in North America for the biomedical community."

Notice to shareholders under Bylaw No. 4

The company would like to inform its shareholders that it has recently received, according to the provisions of Bylaw No. 4 adopted by the company on Aug. 20, a shareholder's notice to the effect that he will be presenting five board members (but excluding the CEO, Clement Forget, and the chairman Lisane Dostie, independent member) to be elected at the general annual meeting on Oct. 28, 2014. The company notes that three of the five members presented by that shareholder are current board members of the company, which will also be presented in the management information and proxy circular to be mailed in the next few days.